BEIJING – CF Pharmtech Inc., of Suzhou, China, closed a ¥630 million (US$90 million) series E financing round to bring its inhaled respiratory drugs to global markets and replace imports with homegrown products faster.
Artificial intelligence (AI) health care startup Cardiologs Technologies SAS scooped up $15 million in a series A funding round led by Alven Capital Partners. The Paris-based company, which has an artificial intelligence-based platform to quickly diagnose cardiac arrhythmias, plans to use the money to grow its sales and marketing efforts across North America and Europe. The funds will also be used to advance the platform’s capabilities. Also participating in the financing were previous investors Bpifrance, Isai, Kurma Diagnostics, Idinvest Partners and Paris Saclay Seed Fund.
BEIJING – China-U.S. biotech Transcenta Holding Ltd., headquartered in Shanghai and Boston, completed a series B+ financing round to secure $100 million to continue its efforts in developing oncology and bone disorder drugs and to prepare for an IPO.
NBE Therapeutics AG raised $22 million in a series C round to take its first antibody-drug conjugate (ADC), NBE-002, into the clinic. NBE-002, which targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in development for both solid tumors and lymphomas
What does the landscape look like in terms of funding for digital health? Geoffrey Starr, a partner at Cooley LLP, dove into this question during the Digital Health Summit, part of CES 2020. He acknowledged that 2019 saw a slight dip in funding compared with the record-breaking previous year. With that said, it was the second largest year ever for digital health care financings, with more than one-third of all health care venture financings involving digital health technologies.
HONG KONG – South Korean-based med-tech Lunit Inc., of Seoul, has secured ₩30 billion (US$25.6 million) in series C funding. Founded in 2013, the Korean company has raised $50 million so far. Lunit’s corporate value was evaluated at as much as ₩200 billion as of the fundraising.
It’s a big day for privately held Empirico Inc. as it embarks on a massive combo pharma deal with Ionis Pharmaceuticals Inc. while racking up a $17 million series A-2 financing.
RSS
